Safety Monitoring System Articles & Analysis
1 news found
Reporting of primary endpoint on track for Q4 2022 FDA regulatory submission on track for mid-2023 70% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to published literature in this high-risk patient population Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment ...